Increasing chronic diseases, longer hospitalization duration, and government initiatives is expected to expand the market over the forecast period

1. Follow Us:
Intravenous Solutions Market Analysis, Size, Growth, Share &
Forecast to 2024 | Grand View Research Inc.
The global IV solutions market was valued at USD 6.9 billion in 2015 and is expected to reach a value of
USD 13.79 billion by 2024. Key factors driving market expansion include the rapidly increasing natality rate
including a high percentage of premature births and malnutrition.
Growing incidence rate of chronic diseases, such as cancer, is also fueling the demand for Total Parenteral
Nutrition (TPN), which forms a vital part of the treatment. Intravenous nutrition helps sustain strength,
maintains hydration levels in patients, and facilitates faster recovery. Cancer prevalence is forecasted to grow
by 70% over the next few decades. This poses a colossal growth prospect for the market.
The regulatory bodies are approving high-quality products complying with faster patient recovery. In May 2016,
Amanta Healthcare received approval for NaCl injection BP and Sterile water injection BP products. These
products obtained Therapeutic Goods Administration approval granted by the Australian government.
The reimbursement scenario for IV nutrition is promising. In the U.S., Medicare covers up to 80% of the
expenses of parenteral and enteral nutrition including physician services, medical equipment, and other related
medical services. In the developing countries, increasing purchasing power compensates for the absence of
reimbursement coverage thus sustaining the growth of this vertical.
Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/intravenous-iv-
solutions-market
“Intravenous Solutions Market Worth $13.79 Billion By 2024”

2. Follow Us:
Further Key Findings From the Study Suggest:
• TPN dominated the market in 2015. TPN is administered to patients who are ‘nil by mouth’ or are
afflicted with dysfunctional digestive systems. Around 2000 elderly deaths occur per annum due to
malnutrition. With rising geriatric population and chronic, but manageable diseases, the demand for
TPN is projected to grow over the forecast period.
• In 2015, North America dominated the market with a revenue share of around 40%. The region has a
large geriatric population base comprising 45% long-term care residents and 40% hospitalized, elderly
patients suffering from malnutrition. Moreover, in 2014, the region experienced a sharp shortage of IV
fluids due to increased hospitalization of influenza patients. In response to the deficit, FDA initiatives
were directed toward expediting the application review process and identifying potential new
manufacturers.
• Asia Pacific is expected to emerge as the fastest growing region. The rising geriatric population in
Japan and China, increasing tendencies of unhealthy food consumption, and low level of awareness is
expected to promote the emergence of IV solutions market in this region.
• Fresenius Kabi AG, Baxter, B. Braun Melsungen AG, and Hospira are few players operating in the
market. Mergers and acquisitions are certain strategic initiatives undertaken by the companies. For
instance, Claris-Otsuka is a joint venture between Claris Lifesciences Ltd., Otsuka Pharmaceutical Co.,
Ltd., and Mitsui & Co., Ltd., Japan established in 2012. This joint venture focused on the manufacturing
and marketing activities for IV nutrition products and offers products in various IV delivery systems.
Grand View Research has segmented the IV solutions market by type, nutrients, and region:
Type Outlook (Market revenue in USD Million, 2013 - 2024)
• Total Parenteral Nutrition (TPN)
• Peripheral Parenteral Nutrition (PPN)
Nutrient Outlook (Market Revenue in USD Million, 2013 - 2024)
• Carbohydrates
• Single dose amino acid solution
• Vitamins & minerals (salt and electrolyte)
• Parenteral lipid emulsion
• Others (trace elements)
Regional Outlook (Market Revenue in USD Million, 2013 - 2024)
• North America
o U.S.

3. Follow Us:
o Canada
• Europe
o UK
o Germany
• Asia Pacific
o Japan
o China
o India
o Australia
• Latin America
o Brazil
o Mexico
• Middle East and Africa
o South Africa
Table of Content
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends& Scope
4.1 Market Segmentation and Scope
4.1.1 Market Driver Analysis
4.1.1.1 Increasing natality rate
4.1.1.2 Risk of malnutrition
4.1.1.3 Rising geriatric population base
4.1.1.4 Increasing incidence of cancer
4.1.2 Market Restraint Analysis

4. Follow Us:
4.1.2.1 Shortage of parenteral nutrition products
4.1.2.2 Increased use of enteral nutrition
4.1.2.3 High risk of infection
4.1.2.4 Stringent regulations
4.2 Penetration & Growth Prospects Mapping
4.3 IV solutions Market - PESTLE Analysis
4.4 Industry Analysis - Porter’s
Chapter 5 Market Categorization 1: Type Estimates & Trend Analysis
5.1 IV solutions Market: Type Movement Analysis
5.2 Total Parenteral Nutrition (TPN)
5.3 Total Parenteral Nutrition (TPN) Market, 2013 - 2024 (USD Million)
5.4 Peripheral Parenteral Nutrition (PPN)
5.4.1 Peripheral Parenteral Nutrition (PPN)Market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Nutrients Estimates & Trend Analysis
6.1 IV solutions Market: Nutrients Movement Analysis
6.2 Carbohydrates
6.2.1 CarbohydratesMarket, 2013 - 2024 (USD Million)
6.3 Vitamins and minerals (Salt and electrolyte)
6.3.1 Vitamins and Minerals (Salt and Electrolyte) Market, 2013 - 2024 (USD Million)
6.4 Single dose amino acids
6.4.1 Single dose amino acids Market, 2013 - 2024 (USD Million)
6.5 Parenteral lipid emulsion
6.5.1 Parenteral Lipid EmulsionMarket, 2013 - 2024 (USD Million)
6.6 Others (trace elements)
6.6.1 Other (trace elements) IV Solutions Market, 2013 - 2024 (USD Million)
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Services
7.1 IV solutions Market Share By Region, 2015 & 2024
7.2 North America
7.2.1 US
7.2.1.1 U.S. IV solutions Market, 2013 - 2024 (USD Million)
7.2.2 Canada
7.2.2.1 Canada IV solutions Market, 2013 - 2024 (USD Million)
7.3 Europe
7.3.1 UK

5. Follow Us:
7.3.1.1 UK IV solutions Market, 2013 - 2024 (USD Million)
7.3.2 Germany
7.3.2.1 Germany IV solutions Market, 2013 - 2024 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific IV solutions Market, 2013 - 2024 (USD Million)
7.4.2 Japan
7.4.2.1 Japan IV solutions Market, 2013 - 2024 (USD Million)
7.4.3 China
7.4.3.1 China IV solutions Market, 2013 - 2024 (USD Million)
7.4.4 India
7.4.4.1 India IV solutions Market, 2013 - 2024 (USD Million)
7.5 Latin America
7.5.1 Latin America IV solutions Market, 2013 - 2024 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil IV solutions Market, 2013 - 2024 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico IV solutions market, 2013 - 2024 (USD Million)
7.6 MEA
7.6.1 MEA IV solutions Market, 2013 - 2024 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa IV solutions Market, 2013 - 2024 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy framework
8.2 Company Profiles
8.2.1 Fresenius Kabi
8.2.1.1 Company overview
8.2.1.2 Financial performance
8.2.1.3 Product benchmarking
8.2.1.4 Strategic initiatives
8.2.2 Sino-Swed Pharmaceutical Corp., Ltd.
8.2.2.1 Company overview
8.2.2.2 Financial performance
8.2.2.3 Product benchmarking
8.2.2.4 Strategic initiatives

6. Follow Us:
8.2.3 Hospira
8.2.3.1 Company overview
8.2.3.2 Financial performance
8.2.3.3 Product benchmarking
8.2.3.4 Strategic initiatives
8.2.4 Amanta Healthcare.
8.2.4.1 Company overview
8.2.4.2 Financial performance
8.2.4.3 Product benchmarking
8.2.4.4 Strategic initiatives
8.2.5 Otsuka Pharmaceutical Co., Ltd.
8.2.5.1 Company overview
8.2.5.2 Financial performance
8.2.5.3 Product benchmarking
8.2.5.4 Strategic initiatives
8.2.6 Sichuan Kelun Pharmaceutical Co., Ltd.
8.2.6.1 Company overview
8.2.6.2 Financial performance
8.2.6.3 Strategic initiatives
8.2.7 Terumo Corporation
8.2.7.1 Company overview
8.2.7.2 Financial performance
8.2.7.3 Product benchmarking
8.2.7.4 Strategic initiatives
8.2.8 Baxter
8.2.8.1 Company overview
8.2.8.2 Financial performance
8.2.8.3 Product benchmarking
8.2.8.4 Strategic initiatives
8.2.9 B. Braun Melsungen AG
8.2.9.1 Company overview
8.2.9.2 Financial performance
8.2.9.3 Product benchmarking
8.2.9.4 Strategic initiatives

7. Follow Us:
8.2.10 Claris Lifesciences Ltd.
8.2.10.1 Company overview
8.2.10.2 Financial performance
8.2.10.3 Product benchmarking
8.2.10.4 Strategic Initiatives
8.2.11 Kyowa Hakko Bio Co., Ltd.
8.2.11.1 Company overview
8.2.11.2 Financial performance
8.2.11.3 Product benchmarking
8.2.11.4 Strategic initiatives
8.2.12 Grifols
8.2.12.1 Company overview
8.2.12.2 Financial performance
8.2.12.3 Product Benchmarking
8.2.12.4 Strategic Initiatives
8.2.13 Liqvor Pharmaceuticals
8.2.13.1 Company Overview
8.2.13.2 Financial Performance
8.2.13.3 Product Benchmarking
8.2.13.4 Strategic Initiatives
8.3 Competition analysis (Strategies)
8.3.1 Baxter plans to build a new intravenous admixing facility in Canada
8.3.2 Fresenius Kabi launches Kabiven in the U.S.
8.3.3 Mallinckrodt acquires Cadence Pharmaceuticals, Inc. for USD 1.4 Billion
8.3.4 Cardiome acquires Correvio LLC
8.3.5 Grifols enters into an agreement with Cumberland Pharmaceuticals to market Ibuprofen for
intravenous infusion
8.3.6 FDA Approves New Large-Volume Intravenous Containers of B. Braun Medical
8.3.7 Fresenius Kabi Forms JV for I.V. Generics
8.3.8 Sandoz launches authorized generic version of Argatroban injection
8.3.9 BPC’s BIVIGAM, a new intravenous immune globulin gains US FDA approval
8.3.10 Hospira recalls electrolyte solution
8.3.11 Otsuka, Mitsui and Claris established an IV solutions joint venture business in India
8.3.12 Kyowa Hakko Kirin Introduces the new NESP INJECTION PLASTIC SYRINGE with

8. Follow Us:
Unified Injection Volume
8.3.13 Taiho Pharmaceutical released 5-HT3 receptor Antagonist Aloxi I.V. infusion bag 0.75mg
8.3.14 Merck to give back Vernakalant’s worldwide marketing and development rights to
Cardiome
8.3.15 Baxter Healthcare to Withdraw Automix Automated Nutrition Compounder Systems
8.3.16 Rienso(ferumoxytol) attains marketing authorization by the European Commission for iron
deficiency anaemia treatment in Adult Chronic Kidney Disease Patients
8.3.17 MTPC’s Label Extension for Remicade Facilitate in Shorter Infusion Time
8.3.18 Shionogi gains pediatric use and additional indication approvals for Purulent Meningitis of
Carbapenem-Type Antibiotic in Japan
8.3.19 Intravenous Solution Manufacturing Plant establishment in Sri Lanka
8.3.20 Hospira, Inc. Introduces Imipenem-Cilastatin for IV injection in the U.S.
8.3.21 Shionogi Introduces Carbapenem-type Antibiotic, Finibax 0.5 g for Intravenous Drip
Infusion
8.3.22 Baxter Acquires Baxa Corporation
8.3.23 Baxter Launches NUMETA, as the first Triple-Chamber IV Nutrition System for premature
newborns and children in Europe
8.3.24 FDA Grants 510(K) clearance to Introcan Safety 3 Closed IV Catheter from B. Braun
Melsungen AG
8.3.25 Becton, Dickinson and Company (BD) Introduces New Generation Short Peripheral IV
Catheter
8.3.26 Mitisubishi Tanabe Introduces Simponi Subcutaneous Injection 50mg Syringe
8.3.27 Benesis’ Venoglobulin IH 5% for Intravenous Injection Receives Approval for Additional
Indications
8.3.28 Mitsubishi Tanabe Receives Approval for Partial Change in Dosage & Usage of Remicade
for I.V. Infusion 100
8.3.29 OLIMEL, First Triple-Chamber Bag for Nutrition, Launched in Canada by Baxter
8.3.30 Daiichi Sankyo launches Cravit intravenous injections
8.3.31 Cadence Pharmaceuticals launches OFIRMEV (acetaminophen) injection, the first and
solitary intravenous formulation of acetaminophen in the U.S.
8.3.32 AmeriCares Enters into a Partnership Agreement with Baxter
8.3.33 Marck Biosciences acquires assets of Goa-based Ravish Infusion
8.3.34 Fresenius Medical Care and Galenica Establish Renal Pharmaceutical Company
8.3.35 Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV

9. Follow Us:
8.3.36 Grifols Announces the Launch of Flebogamma 10% DIF IVIG
8.3.37 Hospira Enters into New Contracts with Novation for Infusion Pumps, Solutions, and
Equipment
8.3.38 Venoglobulin-IH 5% IV Approved for Additional Indications of Dermatomyositis and
Polymyositis
8.3.39 GlaxoSmithKline and Genmab Alter Ofatumumab Development Program in Autoimmune
Indications
8.3.40 BRINAVESS (vernakalant) IV Granted Marketing Approval in the EU for Rapid Conversion
of Recent Onset Atrial Fibrillation
8.3.41 EMA accepts MAA for FERAHEME of AMAG Pharmaceuticals and Takeda
8.3.42 Global Registration Program for FERAHEME to treat iron deficiency anemia initiated
8.3.43 Grifols Acquires Talecris
8.3.44 CareFusion Concludes the Acquisition of Medegen
8.3.45 BioScrip Acquires Critical Homecare Solutions
8.3.46 RADICUT BAG for IV Infusion 30mg, an approved new dosage form of Cerebral
Neuroprotectant RADICUT injection 30 mg
8.3.47 Mitsubishi Tanabe Pharma obtains approval for new indication of Psoriasis
8.3.48 Hospira launches environment friendly IV containers
8.3.49 Evolva SA completes merger with Arpida Ltd.
8.3.50 Claris introduces anti-infective injectable unit
8.3.51 Pfizer completes acquisition of Wyeth
8.3.52 Celldex Therapeutics completes acquisition of CuraGen Corporation
8.3.53 HYLENEX, Commercially Launched by Baxter
8.3.54 Hospira Enters into a new agreement with MedAssets for IV solutions and renews infusion
devices agreement
8.3.55 Marck Biosciences enters Singapore and Malaysia
8.3.56 Baxter and SIGMA signed an exclusive distribution agreement for infusion pumps
8.3.57 Talecris Biotherapeutics launches Gamunex Connexions Certificate Program
8.3.58 Gamunex of Talecris Biotherapeutics approved by the U.S. FDA as treatment for
Neurological Disorder CIDP
8.3.59 Arpida Files New Drug Submission for Intravenous Iclaprim in Canada
8.3.60 Fresenius Medical Care closes US license agreement for intravenous iron products
8.3.61 Antimicrobial IV Technology of Baxter demonstrates capability to eliminate six pathogens
inclusive of MRSA and VRE

10. Follow Us:
8.3.62 Hospira enters into new contract with Premier Purchasing Partners for infusion devices,
solutions, and equipment
8.3.63 Arpida files Marketing Authorization Application in Europe for intravenous Iclaprim
8.3.64 Fresenius Medical Care enters into agreement for intravenous iron products
8.3.65 Otsuka Pharmaceutical Co., Ltd.and PDL BioPharma Concluded the Sale of IV Busulfex
8.3.66 Fresenius Kabi expands infusion therapy business in Latin America
8.3.67 Otsuka to Acquire Busulfex IV from PDL BioPharma
8.3.68 Hospira obtains marketing authorization in the EU for Retacrit
8.3.69 Voluven - product for prevention and treatment of severe blood volume loss following
surgery - approved by the FDA
8.3.70 New safety packaging introduced by Baxter for high-alert drugs
8.3.71 Transition to NextGen IV Immunoglobulin- Flebogamma DIF - Concluded in record time in
the U.S. by Grifols
8.3.72 Kyowa Hakko and Kirin Groups Formalize Strategic Alliance Agreement
8.3.73 Baxter in joint venture with Guangzhou Baiyunshan Pharmaceutical Co., Ltd. for parenteral
nutritional products in China
8.3.74 EMEA authorizes NextGen IVIG distribution in the European Union
8.3.75 Kyowa Hakko increases amino acid prices in Europe
8.3.76 Shanghai Century Acquisition Corporation acquires the shares of Sichuan Kelun
Pharmaceutical Co., Ltd.
8.3.77 Advanced NutriSolutions acquires Select Supplements from Kyowa Hakko
8.3.78 Mayne Pharma acquisition process completed by Hospira, Inc.
8.3.79 FDA issues Marketing License to Grifols for NextGen Intravenous Immunoglobulin (IVIG)
in the US
8.3.80 Kyowa Hakko releases White Paper Kit attributed to amino acids and related compounds
8.3.81 Symbiq - The Next-Gen Infusion System from Hospira, Inc.
8.3.82 Health Alliance of Greater Cincinnati to replace its entire fleet of IV pumps across seven
hospitals
8.3.83 Amigrand Intravenous Infusion Launched Jointly by Tanabe Seiyaku and Terumo
8.3.84 Systemic fungal infection therapy AmBisome 50 mg for intravenous drip infusion -
launched
8.3.85 A new line of intravenous solutions - AVIVA from Baxter
8.3.86 Cadence Pharmaceuticals acquires rights to IV APAP
8.3.87 BioScrip Inc. launches specialty infusion operations on Western Coast by acquiring

11. Follow Us:
Intravenous Therapy Services
8.3.88 Boniva - The First Intravenous Medication to treat Postmenopausal Osteoporosis,
Approved by the FDA
8.3.89 Ajinomoto acquires Amoy Food Group from Groupe Danone
8.3.90 FLEXBUMIN- the flexible container packaged Albumin solution from Baxter, approved
Chapter 9 Product technology/Research
9.1 Composition
9.1.1 Application
9.2 Packaging And Identification Labeling Of APIs And Intermediates
9.2.1 General
9.2.2 Packaging Materials
9.2.3 Label Issuance and Control
9.2.4 Packaging and Labeling Operations
9.3 Storage And Distribution
9.3.1 Storage
9.3.2 Warehousing Procedures
9.3.3 Distribution Procedures
9.4 Specific Guidance For APIs Manufactured By Cell Culture/Fermentation
9.4.1 General
9.4.2 Cell Culture/Fermentation
9.4.3 Harvesting, Isolation and Purification
9.4.4 Viral Removal/Inactivation steps
9.5 Safety Assessment of Di (2-ethylhexyl) phthalate (DEHP) Released from PVC Medical Devices
9.5.1 Conclusions of the Safety Assessment
9.5.1.1 I V Infusion of Crystalloid Fluids and Drugs
9.5.1.2 Total Parenteral Nutrition (TPN)
9.6 Government of India - Policy and Regulations on Drugs
9.6.1 Drug Regulation and Control
9.6.2 Procedure for Drug Application in India
9.6.2.1 List of documents required to be submitted
9.6.3 Import and Manufacturing Licenses and Approvals
9.6.4 Labeling Requirements
9.6.5 Drug Price Regulation
9.6.6 Trends in Drug Price Control - India

12. Follow Us:
9.6.7 Regulations on Patent Protection
9.7 Intravenous Solutions - Research Briefs
9.7.1 Intravenous Food Ingredients Leading to Liver Damage, Identified
9.7.2 International Dispute Regarding Intravenous Nutrition Administration May Have Been
Resolved
9.7.3 Enteral Nutrition More Effective than TPN in Severe Acute Pancreatitis
9.7.4 Survival Period Post Hospital Discharge is Not Dependent on Intravenous Drug
Administration
9.7.5 Intravenous Infusion Solution Ingredients Trigger Inflammation
9.7.6 Early Nasogastric-Enteral Nutrition for Managing Severe Acute Pancreatitis
About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based research across a range of
industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: http://www.grandviewresearch.com